GlassScriptPhysician profile
Mary E Gaeke
NPI 1134180664
$2,867.95
in general payments reported to CMS, 2019-2025
34 companies · $76.95 in 2025
The $76.95 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,710 · 2023: $1,021 · 2024: $60.02 · 2025: $76.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.62 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $273.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $260.18 | 2022-2023 | Reblozyl, Opdivo |
| Glaxosmithkline, LLC. | $260.01 | 2022-2023 | Jemperli, Zejula |
| Janssen Biotech, INC. | $250.09 | 2022-2023 | Darzalex, Imbruvica |
| Regeneron Healthcare Solutions, INC. | $206.90 | 2022-2023 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $158.03 | 2022-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $146.78 | 2023 | |
| Kite Pharma, INC. | $123.05 | 2023 | |
| Cti Biopharma Corp. | $101.45 | 2022 | |
| Beigene USA, INC. | $97.41 | 2022 | |
| Karyopharm Therapeutics INC. | $97.05 | 2022 | |
| Blueprint Medicines Corporation | $92.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.16 | 2022 | |
| Pfizer INC. | $70.85 | 2022-2023 | |
| Genentech USA, INC. | $63.79 | 2024-2025 | Gazyva, Itovebi, Tecentriq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $60.29 | 2022-2025 | Enhertu |
| Incyte Corporation | $54.78 | 2022-2023 | Monjuvi, Jakafi, Pemazyre |
| Merck Sharp & Dohme LLC | $52.08 | 2023-2025 | Keytruda, Keytruda Qlex, Reblozyl |
| Genzyme Corporation | $47.70 | 2022-2023 | |
| Array Biopharma INC | $35.43 | 2023 | Mektovi, Braftovi, Lorbrena |
| Seagen INC. | $34.30 | 2022-2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $31.23 | 2022-2023 | |
| Astellas Pharma US INC | $29.99 | 2022-2023 | Padcev |
| Alexion Pharmaceuticals, INC. | $29.80 | 2022-2023 | Ultomiris |
| Celgene Corporation | $29.58 | 2022-2023 | Reblozyl |
| Amgen INC. | $23.44 | 2022 | |
| Emd Serono, INC. | $21.49 | 2023 | Tepmetko |
| Genmab U.S., INC. | $20.78 | 2023 | Tivdak |
| Pharmaessentia USA Corporation | $20.69 | 2023 | Besremi |
| Taiho Oncology, INC. | $20.69 | 2022 | |
| Adaptive Biotechnologies Corporation | $19.28 | 2022 | |
| Eisai INC. | $16.90 | 2024 | |
| Gilead Sciences, INC. | $15.95 | 2023 | Trodelvy |
| G1 Therapeutics, INC. | $13.70 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Gaeke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.